BDSI Completes Clinical Trials for its Formulation of Emezine

BioDelivery Sciences International (BDSI) has completed the clinical studies required for its pending new drug application on Emezine, a buccal product for the treatment of nausea and vomiting.

Emezine will be the first product in the U.S. market for the treatment of nausea and vomiting to be provided via a buccal (across the cheek membrane) delivery system. BDSI, through its Arius Pharmaceuticals subsidiary, licenses Emezine from a third-party pharmaceutical company.

BDSI's Emezine product is administered by placing a tablet between the gum and the cheek where it dissolves, enabling the active ingredient to be absorbed through the lining of the cheek. This formulation provides for a rapid onset of action and an alternative to swallowed tablets, suppositories or injections. BDSI believes that delivering an antinausea drug transbuccally may offer advantages over traditional delivery methods.